Compare CTXR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTXR | TVRD |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.6M |
| IPO Year | 2010 | 2013 |
| Metric | CTXR | TVRD |
|---|---|---|
| Price | $0.51 | $0.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | ★ 253.3K | 184.7K |
| Earning Date | 12-22-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.38 | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.37 | $0.77 |
| 52 Week High | $1.54 | $5.69 |
| Indicator | CTXR | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 43.90 |
| Support Level | $0.47 | $0.85 |
| Resistance Level | $0.63 | $1.09 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 22.42 | 20.86 |
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.